Adocia: Successful Phase 3 in China for BioChaperone Lispro, $20M in Sight

Confirmed Non-Inferiority with Targeted Clinical Benefits

The THDB0206L02 study, which involved more than 1,000 type 2 diabetes patients, confirmed the non-inferiority of BioChaperone Lispro in reducing HbA1c across the population. Its safety profile proved equivalent to that of Humalog, the reference treatment developed by Eli Lilly.

Beyond these primary endpoints, Adocia's ultra-rapid insulin demonstrated better glycemic control in patients on metformin or those with levels below 8.5%. The trial also highlighted improved glycemic control throughout the day and after each meal for the entire population studied.

A Candidate Advancing Towards Regulatory Development in China

BioChaperone Lispro was licensed to Tonghua Dongbao in 2018 for China and other Asian countries. The Chinese partner is currently preparing to file for marketing authorization in China, under its responsibility. According to the licensing agreement, Adocia will receive a milestone payment of $20 million upon approval, as well as double-digit royalties on future sales.

A Virtual Event to Detail the Data

Adocia is organizing a virtual event on June 16, 2026, at 10 AM EST (4 PM CEST) with Dr. Tim Heise, lead researcher, chairman of the board, and co-founder of the Profil research institute based in Neuss, Germany, specializing in early-phase studies on diabetes treatments. Olivier Soula, CEO and co-founder of Adocia, along with You-Ping Chan, head of R&D, will discuss the detailed results of the phase 3 trial.